Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label,Phase I, Dose-escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetic, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate BAY1187982 in Subjects With Advanced Solid Tumors Known to Express FGFR2.

NCT02368951 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02368951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02368951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label,Phase I, Dose-escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetic, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate BAY1187982 in Subjects With Advanced Solid Tumors Known to Express FGFR2.
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Terminated
Start date
March 24, 2015
Completion date
July 27, 2016
Enrollment
20 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

medical oncology